Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 8c
August 3, 2022 4:41 PM EDTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.05, $0.08 worse than the analyst estimate of $0.13. Revenue for the quarter came in at $64.4 million versus the consensus estimate of $67 million.
GUIDANCE:
Vanda Pharmaceuticals sees Q3 2022 revenue of $240-280 million, versus the consensus... More
